Research programme: antifungals - GPC Biotech

Drug Profile

Research programme: antifungals - GPC Biotech

Alternative Names: Cak1 inhibitors - GPC Biotech; GGTase inhibitors - GPC Biotech

Latest Information Update: 05 May 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GPC Biotech Inc
  • Class Small molecules
  • Mechanism of Action CDC2 protein kinase inhibitors; Geranylgeranyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Mycoses

Most Recent Events

  • 05 May 2003 This antifungal research programme is available for licensing (
  • 11 May 2000 Preclinical development for Mycoses in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top